Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOVENT vs AEROLONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
Treatment of symptoms and prevention of asthma,Treatment of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Treatment of bronchospasm in patients with COPD,Long-term maintenance treatment of asthma
Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.
AEROLONE is not a recognized drug; no standard dosing available.
Terminal elimination half-life 7-9 hours, prolonged in patients with hepatic impairment (up to 12 hours) or heart failure.
Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Primarily hepatic via CYP1A2, CYP2E1, and CYP3A4. Metabolites include 3-methylxanthine, 1-methyluric acid, and 1,3-dimethyluric acid.
Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites).
Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%.
40% bound primarily to albumin.
Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein.
0.3-0.5 L/kg, approximating total body water.
3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding.
Oral immediate-release: 96%; sustained-release: 80-90%.
Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%.
GFR 30-50 m L/min: reduce dose by 25%. GFR 10-29 m L/min: reduce dose by 50%. GFR <10 m L/min: reduce dose by 75% or extend interval to every 24 hours.
No data; not applicable.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75% or consider alternative therapy.
No data; not applicable.
Oral: 5-10 mg/kg every 12 hours; maximum 400 mg/day. Intravenous: 5 mg/kg loading dose, then 5 mg/kg every 12 hours.
No data; not applicable.
Initiate at 200 mg every 12 hours; increase cautiously to 400 mg every 12 hours; monitor renal function and adjust per renal guidelines.
No data; not applicable.
No FDA black box warning.
None
High risk of toxicity with narrow therapeutic index; monitor serum levels,Use caution in patients with cardiac disorders (e.g., arrhythmias), liver disease, renal impairment, seizure disorders, or peptic ulcer disease,Drug interactions with fluoroquinolones, macrolides, cimetidine, allopurinol, and others can increase theophylline levels,Cigarette smoking and certain anticonvulsants can decrease theophylline levels
Paradoxical bronchospasm,Cardiovascular effects (e.g., increased heart rate, QT prolongation),Hypokalemia,Hyperglycemia
Hypersensitivity to theophylline or any component,Seizure disorder not adequately controlled,Active peptic ulcer disease
Hypersensitivity to arformoterol or any component of the formulation
Avoid high-fat meals as they can alter absorption of sustained-release formulations. Caffeine-containing foods and beverages (coffee, tea, cola, chocolate) may increase the risk of toxicity and should be limited. Charcoal-grilled foods and a high-protein diet may reduce theophylline clearance, while a high-carbohydrate diet may increase clearance; maintain consistent diet.
No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component.
First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnancy category C.
No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure.
Excreted in breast milk; M/P ratio approximately 0.6; use with caution, monitor infant for irritability and tachycardia.
Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation).
Increased clearance in late pregnancy may require dose increase; monitor serum levels and adjust to maintain therapeutic range (5-15 mcg/m L).
No specific dose adjustment required based on pharmacokinetic changes; pregnancy may cause decreased airway reactivity but no significant changes in fluticasone clearance. Maintain lowest effective dose to control asthma. No dose increase recommended solely due to pregnancy. Monitor asthma control and adjust dose as per standard guidelines.
THEOVENT is a brand of theophylline, a methylxanthine bronchodilator. Narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with seizure disorders. Use with caution in heart failure, hepatic impairment, and elderly. Caffeine and other methylxanthines can increase toxicity. Smoking induces metabolism, requiring dose adjustments. Consider alternative in acute exacerbations due to slow onset.
AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it can increase side effects.,Do not smoke or stop smoking without medical advice, as smoking affects how the drug works.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Take with food if gastrointestinal upset occurs.,Do not crush or chew extended-release tablets; swallow whole.,Keep a regular dosing schedule to maintain consistent blood levels.
Use AEROLONE exactly as prescribed; do not exceed recommended dose.,Rinse your mouth with water after each use (do not swallow) to prevent thrush.,This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you.,Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing.,Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOVENT vs AEROLONE, answered by our medical review team.
THEOVENT is a Bronchodilator that works by Theovent is a brand name for theophylline, a xanthine derivative that acts as a bronchodilator by inhibiting phosphodiesterase, leading to increased intracellular c AMP levels, and by antagonizing adenosine receptors.. AEROLONE is a Bronchodilator that works by Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOVENT and AEROLONE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOVENT is: Oral: 200-400 mg every 12 hours; maximum 800 mg/day. Intravenous: 200 mg loading dose over 30 minutes, then 200 mg every 12 hours.. The standard adult dose of AEROLONE is: AEROLONE is not a recognized drug; no standard dosing available.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOVENT and AEROLONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOVENT is classified as Category C. First trimester: No evidence of major malformations; second/third trimester: Risk of fetal tachycardia and intrauterine growth restriction with high maternal doses; overall pregnan. AEROLONE is classified as Category C. No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled stu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.